Open AccessDecreased sensitivity to paroxetine-induced inhibition of peripheral blood mononuclear cell growth in depressed and antidepressant treatment-resistant patients
Author(s) -
Szymon Rzeźniczek,
M Obuchowicz,
Wojciech Datka,
Marcin Siwek,
Dominika Dudek,
Katarzyna Kmiotek,
Keren Oved,
Noam Shomron,
David Genevieve,
Andrzej Pilc
Publication year - 2016
Publication title -
translational psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.652
H-Index - 82
ISSN - 2158-3188
DOI - 10.1038/tp.2016.90
Subject(s) - paroxetine , antidepressant , major depressive disorder , serotonin transporter , peripheral blood mononuclear cell , serotonin reuptake inhibitor , medicine , pharmacology , reuptake inhibitor , fluoxetine , psychology , serotonin , biology , receptor , in vitro , biochemistry , amygdala , hippocampus
Major depression disorder (MDD) is the most widespread mental disorder. Selective serotonin reuptake inhibitors (SSRIs) are used as first-line MDD treatment but are effective in <70% of patients. Thus, biomarkers for the early identification of treatment-resistant (TR) MDD patients are needed for prioritizing them for alternative therapeutics. SSRI-induced inhibition of the growth of peripheral blood mononuclear cells (PBMCs) is mediated via their target, the serotonin transporter (SERT). Here, we examined whether antidepressant drug-induced inhibition of the growth of PBMCs differed between MDD patients and healthy controls. PBMCs from well-characterized 33 treatment-sensitive (TS) and 33 TR MDD patients, and 24 healthy volunteers were studied. Dose-dependent inhibition of PBMCs growth was observed for both the non-SSRI antidepressant mirtazapine and the SSRI antidepressant paroxetine. Significantly lower sensitivities to 20 μ m paroxetine were observed in MDD compared with control PBMCs prior to treatment onset (13% and 46%, respectively; P< 0.05). Following antidepressant drug treatment for 4 or 7 weeks, the ex vivo paroxetine sensitivity increased to control levels in PBMCs from TS but not from TR MDD patients. This suggests that the low ex vivo paroxetine sensitivity phenotype reflects a state marker of depression. A significantly lower expression of integrin beta-3 ( ITGB3 ), a co-factor of the SERT, was observed in the PBMCs of MDD patients prior to treatment onset compared with healthy controls, and may explain their lower paroxetine sensitivity. Further studies with larger cohorts are required for clarifying the potential of reduced PBMCs paroxetine sensitivity and lower ITGB3 expression as MDD biomarkers.